Current drug delivery最新文献

{"title":"mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons.","authors":"Gaurav Mishra, Sunny Rathee, Munish Garg, Umesh K Patil","doi":"10.2174/0115672018320938241121075859","DOIUrl":"10.2174/0115672018320938241121075859","url":null,"abstract":"<p><p>In recent years, there have been notable strides in developing mRNA vaccines, resulting in the creation of potent immunizations against diverse diseases. This review examines the most recent advancements in this field, focusing on their implications for future vaccine development. The pursuit of heightened vaccine efficacy is investigated through cutting-edge methods in adjuvant selection, delivery system optimization, and antigen selection. The review also explores the potential for personalized vaccines based on genetic profiles, along with the latest techniques to ensure vaccine stability and extend shelf life. Highlighting the versatility of mRNA vaccines in addressing emerging infectious diseases and their variations, the review underscores the significance of swift response plans and advanced technologies to counter evolving viral mutations. In summary, this in-depth analysis emphasizes how mRNA vaccines hold transformative potential in reshaping both therapeutic and preventive strategies. Notable achievements include the creation of extremely potent mRNA vaccinations against the SARS-CoV-2 virus, resulting in the COVID-19 pandemic. Ongoing efforts to address challenges like long-term immune protection and increase the effectiveness and stability of mRNA vaccines are also discussed. This review's main goal is to provide a thorough summary of current advancements in mRNA vaccine technology while exploring how these advances may impact future approaches to treating and preventing different diseases.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"351-372"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide-Loaded Nanoparticles: A Precision Approach to Breast Cancer Treatment.","authors":"Lina Eltaib, Mashael N Alanazi, Mudasir Maqbool, Amita Joshi Rana, Yumna Khan, Md Sadique Hussain","doi":"10.2174/0115672018398707250911054410","DOIUrl":"10.2174/0115672018398707250911054410","url":null,"abstract":"<p><p>Breast cancer (BC) continues to be the most prevalent cause of death from cancer on a global scale, requiring novel and targeted therapeutic strategies. Peptide-loaded nanoparticles (NPs) have been established as a prospective platform for precision drug delivery in BC treatment, providing enhanced cancer selectivity, improved drug stability, and reduced systemic toxicity. This article explores the multifaceted utilizations of peptide-loaded NPs in BC therapeutics, highlighting advancements in targeted drug delivery, combination therapy, and vaccine development. Peptideloaded NPs have demonstrated superior efficacy in delivering chemotherapeutic agents, overcoming drug resistance, and minimizing adverse effects. Studies on tumor-homing peptides, such as F3- functionalized liquid crystalline NPs and tLyP-1-modified reconstituted high-density lipoprotein NPs, have shown significant improvements in drug accumulation at tumor sites, reduction in metastasis, and prolonged circulation time. Additionally, the creation of peptide-based vaccines targeting tumor-associated antigens, including HER2/neu and heat shock protein 90 (HSP90), is reshaping BC immunotherapy, stimulating strong immune responses against tumors. Despite these advancements, obstacles persist in ensuring NP stability, mitigating immunogenicity, and scaling up manufacturing for clinical translation. Future directions include the integration of peptide-loaded NPs with CRISPR/Cas9 for gene-editing applications, the development of peptide nanovaccines, and the use of personalized nanomedicine approaches tailored to the molecular profiles of individual tumors. This review underscores the potential of peptide-loaded NPs as a next-generation therapeutic strategy, facilitating the development of more efficient and personalized treatments for BC.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"300-318"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefadroxil-Mupirocin Integrated Electrospun Nanofiber Films for Burn Wound Therapy.","authors":"Saman Rashid, Munaza Ijaz, Sana Rafique, Haya Yasin, Mahnoor Mushtaq, Abida Kalsoom Khan, Madiha Khan, Bushra Nasir, Ghulam Murtaza","doi":"10.2174/0115672018374558250607134659","DOIUrl":"10.2174/0115672018374558250607134659","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to fabricate dual drug-loaded nanofibrous films made from polyvinyl alcohol (PVA) and chitosan, incorporating cefadroxil and mupirocin to meet the critical needs of burn wound care.</p><p><strong>Methods: </strong>Electrospinning was utilized to fabricate cefadroxil- and mupirocin-loaded polyvinyl alcohol PVA/Chitosan nanofibers. Characterization of structural and morphological properties of these nanofibers was done through Fourier Transform IR Spectroscopy, Scanning Electron Microscopy, Thermal analysis by TGA, and XRD spectroscopy. The kinetic profiles of the drug release mechanisms were considered to determine the release of cefadroxil and mupirocin. Antibacterial activity was determined against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, while the wound healing efficacy was tested in a rabbit model using full-thickness wounds.</p><p><strong>Results: </strong>SEM analysis demonstrated the formation of uniform and smooth nanofibers possessing a well-defined morphology. FTIR spectroscopy confirmed the successful incorporation of cefadroxil and mupirocin into the PVA/Chitosan matrix. TGA analysis indicated the thermal stability of the nanofibers, while XRD results suggested that the drugs were either molecularly dispersed or in an amorphous state within the biopolymeric blend. Drug release studies showed distinct profiles, with an initial burst release followed by sustained drug release. Over 80% of mupirocin was released within the first 2 hours, while cefadroxil exhibited a cumulative release exceeding 60%. Antibacterial assays showed significant inhibition zones, with the largest being 20 mm against Staphylococcus aureus. In vivo studies utilizing a full-thickness rabbit wound model revealed that the drug-loaded nanofibers accelerated wound contraction, achieving approximately 90% closure by day 17, compared to less than 70% for the control.</p><p><strong>Discussion: </strong>The dual drug-loaded PVA/Chitosan nanofiber films demonstrated excellent antibacterial efficacy and improved wound healing, indicating their therapeutic potential for burn wound management. The combination of cefadroxil and mupirocin within the nanofiber matrix enabled rapid initial drug release followed by sustained delivery, contributing to effective infection control and tissue regeneration.</p><p><strong>Conclusion: </strong>The study demonstrates that cefadroxil-mupirocin nanofiber films provide superior antibacterial activity and faster wound healing rates, highlighting their potential in advanced burn wound management.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"735-745"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13555835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidneys Toxicity and Biodistribution of Albumin-Based Gold and Silver Nanoclusters.","authors":"Hussein Alhawari, Sameeha AlShelleh, Nisreen Abu Shahin, Mahmoud Alkawareek, Reem Alabbassi, Maryam K El-Zubi, Rania Mahafdeh, Karem H Alzoubi, Alaaldin M Alkilany","doi":"10.2174/0115672018369974250321004041","DOIUrl":"10.2174/0115672018369974250321004041","url":null,"abstract":"<p><strong>Introduction: </strong>The interaction of the kidneys with nanoparticles is a fundamental issue that accelerates the proper design of efficient and safe nanotherapeutics. The present study aimed to establish the kidney toxicity and the biodistribution profile of novel gold and silver nanocluster formulations.</p><p><strong>Methods: </strong>Gold and silver nanoclusters were synthesized in an albumin template to probe their kidney- nano interaction. The interaction was performed on healthy animals to unveil the toxicity of nanoclusters on kidney tissue.</p><p><strong>Results: </strong>Albumin-based gold nanoclusters (BSA-AuNCs) and albumin-based silver nanoclusters (BSA-AgNCs), exhibited comparable core size (2.2±1.3 nm and 2.5±1.6 nm, respectively) and hydrodynamic diameter (11.3±2.1 nm for BSA-AuNC and 10.7±1.9 nm for BSA-AgNC) indicating similarity in their core and overall sizes. Zeta potential measurements demonstrated a comparable surface charge between BSA- AuNC (18.1±3.2 mV) and BSA- AgNC (20.1±3.6 mV), which closely resembled the surface charge of albumin in water (20.7±3.5 mV). Upon administration to rats via intravenous route, ICP-OES measurements showed a significant silver and gold nanocluster accumulation in various vital organs with unequal distribution patterns. BSA-AgNC exhibited higher concentrations in the liver and spleen, while BSA-AuNC showed predominant accumulation in the liver and kidneys. However, the administered BSA-AgNC induced more renal damage than BSA- AuNCs.</p><p><strong>Conclusion: </strong>The identified renal toxicity linked to BSA-AgNCs, despite their lower kidney accumulation than BSA-AuNCs, illuminates the intricate interplay between nanoparticle biodistribution and toxicity. This underscores the significance of considering the core metal type in nanoparticle design and evaluation. Further investigation is needed to clarify the underlying molecular mechanisms of the observed biodistribution and toxicity.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"475-482"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation of Dual-Drug-Loaded Liver-Targeted Liposomes Co-Modified with SP94 Peptide and TAT Peptide.","authors":"Lin Jing, Simei Luo, Ye Gan, Lili Li, Haotian Wu, Jiajia Zhang, Xu Liu, Mingqing Yuan","doi":"10.2174/0115672018371655251022113914","DOIUrl":"10.2174/0115672018371655251022113914","url":null,"abstract":"<p><strong>Introduction: </strong>The toxicity of nontargeted chemotherapy hinders liver cancer treatment. This study developed dual-peptide (SP94/TAT) co-modified liposomes (SP94/TAT-DOX/DTX-LPs) for enhanced targeting and efficacy.</p><p><strong>Methods: </strong>Liposomes encapsulating docetaxel (DTX) and doxorubicin (DOX) were prepared via film dispersion/ammonium sulfate gradient using DSPE-PEG, lecithin, and cholesterol. SP94 (targeting) and TAT (penetrating) peptides were conjugated via organic phase reaction/insertion. Their physicochemical properties, encapsulation efficiency, stability, drug release, and in vitro antitumor activity were evaluated.</p><p><strong>Results: </strong>Optimized SP94/TAT-DOX/DTX-LPs were spherical (119.6 ± 4.1 nm; PDI 0.161 ± 0.006; zeta -9.84 ± 1.54 mV), and their encapsulation efficiency was high (DOX: 92.97 ± 1.73%; DTX: 80.33 ± 0.96%). Stability was confirmed at 4 °C for 30 days (PDI < 0.2, size change < 10%) and in 50% fetal bovine serum (FBS) for 24 hours (transmittance > 90%). Sustained release showed 68.2 ± 3.5% (DTX) and 74.8 ± 2.9% (DOX) cumulative release at 48h (PBS pH 7.4). In vitro, SP94/TATDOX- LPs showed 2.3-fold higher HepG2 cellular uptake versus single-modified liposomes (p<0.001), with minimal LO2 uptake. Cytotoxicity assays revealed a 3.11-fold lower IC50 (0.096 ± 0.026 μg/mL) versus unmodified liposomes (0.299 ± 0.103 μg/mL). Apoptosis was significantly higher (39.5% in HepG2) than in single-modified formulations (20.55-26.74%).</p><p><strong>Discussion: </strong>SP94/TAT-LPs enable dual-stage targeting: SP94 targets liver cancer cells, and TAT enhances penetration, significantly improving in vitro antitumor activity. Study limitations include sole in vitro validation (HepG2/LO2), small sample size (n=3), parameter variability, and lack of in vivo data on targeting, pharmacokinetics, and toxicity.</p><p><strong>Conclusion: </strong>SP94/TAT-DOX/DTX-LPs achieved effective dual-stage targeting and synergistic cytotoxicity. High encapsulation, stability, and sustained release support their potential as a targeted platform for liver cancer therapy, reducing off-target toxicity.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"681-697"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145992601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell Culture and Molecular Docking Analysis to Determine the Antiviral Activity of Folklore Medicinal Plants Against Chikungunya Virus.","authors":"Sukender Kumar, Samander Kaushik, Munish Garg","doi":"10.2174/0115672018307676240827103052","DOIUrl":"10.2174/0115672018307676240827103052","url":null,"abstract":"<p><strong>Introduction: </strong>Chikungunya Virus (CHIKV), a mosquito-transmitted pathogen, poses a significant global health threat owing to its widespread prevalence and high morbidity. There are no approved vaccines or antivirals for prevention or treatment. Screening of folklore medicinal plants has emerged as a promising approach to finding novel therapeutics to combat pathogens. Hence, this study aimed to evaluate the anti-chikungunya potential of folklore medicinal plants and their phytochemicals.</p><p><strong>Methods: </strong>Maximum non-toxic concentrations (MNTD) of the extracts to Vero cells were determined by the cytotoxicity assay. A Focus-Forming Unit (FFU) assay was used to assess the antiviral activity of the extracts (at MNTD) against CHIKV in Vero cells under pre-, co-, and post-treatment conditions. GC-MS was used to detect the phytochemicals of the extracts, and Schrodinger (Maestro) software was employed for their molecular docking against the target protein of CHIKV.</p><p><strong>Results: </strong>Azadirachta indica exhibited anti-CHIKV activity during pre- and post-treatment, decreasing the virus titer from 8.145 to 7.998 and 8.361 to 8.040 mean log10 FFU/ml, respectively. Calendula officinalis and Piper retrofractum exhibited anti-CHIKV activity only during post-treatment (8.361 to 8.135, 8.361 to 8.075). Moreover, molecular docking studies of phytochemicals detected in GCMS analysis of all the extracts revealed that many phytochemicals (especially F3, F5, F6, and A1) could bind to the non-structural protein (nSP2) target of CHIKV and suppress the viral replication.</p><p><strong>Conclusion: </strong>The screened plants showed the ability to inhibit CHIKV infection and replication and hold potential for further investigation in developing treatments for Chikungunya.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"373-387"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Solubility and α-Glucosidase Inhibition of Mangosteen Peel Extract <i>via</i> Amorphous Solid Dispersion: A Comparative Study of Solvent Evaporation and Fluidized Bed Drying Methods.","authors":"Ahmad Fariz Maulana, Ranya Nur Aisyah, Sriwidodo Sriwidodo, Iman Permana Maksum, Yaya Rukayadi","doi":"10.2174/0115672018422136260130000617","DOIUrl":"https://doi.org/10.2174/0115672018422136260130000617","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes mellitus represents a growing global health burden, with current α-glucosidase inhibitors such as acarbose and miglitol demonstrating limited efficacy and notable gastrointestinal side effects. α-Mangostin, a bioactive compound from mangosteen peel, shows promise as a natural α-glucosidase inhibitor but suffers from poor aqueous solubility. This study aimed to enhance the solubility and enzyme inhibitory activity of mangosteen peel extract through amorphous solid dispersion using two manufacturing approaches: solvent evaporation and fluidized bed drying.</p><p><strong>Methods: </strong>Mangosteen peel extract was formulated into amorphous solid dispersions using polyvinylpyrrolidone K30 at a 1:3 polymer ratio via solvent evaporation and fluidized bed drying methods. Solubility enhancement was evaluated under standardized conditions, and α-glucosidase inhibitory activity was assessed through IC50 determination. Comparative analysis against acarbose and quercetin standards was performed.</p><p><strong>Results: </strong>Solvent evaporation achieved 2.1-fold solubility enhancement, while fluidized bed drying yielded 1.8-fold improvement. The mangosteen peel extract demonstrated superior α-glucosidase inhibition (IC₅₀ = 20.13 ± 0.02 μg/mL) compared to acarbose (IC₅₀ = 379.75 ± 0.57 μg/mL) but remained less potent than quercetin (IC₅₀ = 2.97 ± 0.05 μg/mL). When normalized to equivalent α- mangostin concentrations, fluidized bed drying preserved inhibitory activity more effectively (IC₅₀ = 112.87 ± 0.06 μg/mL) than solvent evaporation (IC50 = 1238.48 ± 0.51 μg/mL).</p><p><strong>Discussion: </strong>The manufacturing method significantly influenced both solubility and biological activity. Solvent evaporation maximized solubility enhancement but compromised enzyme inhibitory potency, whereas fluidized bed drying maintained superior inhibitory activity despite moderate solubility improvement. This trade-off suggests that formulation strategy selection should prioritize the desired therapeutic outcome.</p><p><strong>Conclusion: </strong>Amorphous solid dispersion successfully enhanced both solubility and α-glucosidase inhibitory activity of mangosteen peel extract. Fluidized bed drying represents the optimal manufacturing approach for preserving enzyme inhibition while achieving meaningful solubility enhancement, positioning α-mangostin as a promising candidate for natural antidiabetic drug development.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":"23 8","pages":"984-995"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanosystems for Intranasal Delivery of Therapeutics in Psychiatric Disorders.","authors":"Samin Hamidi, Ali Reza Shafiee-Kandjani, Sara Salatin","doi":"10.2174/0115672018336704241128101556","DOIUrl":"10.2174/0115672018336704241128101556","url":null,"abstract":"<p><p>Due to the blood-brain barrier (BBB) and issues with oral and other traditional routes of administration, psychiatric disorders present significant challenges in getting therapeutics into the brain. The nose-to-brain pathway, also known as intranasal delivery, has shown promise in overcoming these barriers since it targets the brain directly and bypasses the BBB. This review explores nanocarriers' potential for intranasal delivery of therapeutics in the treatment of psychiatric disorders. Nanocarriers, such as polymeric nanoparticles, liposomes, and nanoemulsions, offer unique advantages for enhancing the delivery of various therapeutic agents to the brain via the intranasal route. The methodology involved conducting preliminary searches on databases such as PubMed, ScienceDirect, Web of Science, and Google Scholar using keywords related to \"psychiatric disorders, intranasal delivery, nose-to-brain drug delivery, and nano formulations for intranasal delivery.\" This review highlights the advantages of the intranasal drug delivery pathway as a non-invasive, reliable, and efficient method for targeting the brain by bypassing the BBB. Furthermore, it discusses the application of various novel nanocarrier-based formulations, including nanoparticles, in-situ gels, nanoemulsions, hydrogels, and liposomes, for the effective intranasal delivery of therapeutics in the treatment of psychiatric conditions such as mood and anxiety disorders schizophrenia, and other illnesses.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"144-166"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Developments in Oral Drug Delivery of Prokinetic Agents: Nanoparticles and Beyond.","authors":"Rameshwar Dass, Meenakshi Bhatia, Goutam Rath, Ashwani K Dhingra","doi":"10.2174/0115672018296163240910111938","DOIUrl":"10.2174/0115672018296163240910111938","url":null,"abstract":"<p><p>Prokinetic agents are drugs used to enhance gastrointestinal motility and treat disorders such as Gastroesophageal Reflux Disease (GERD) and gastroparesis. pH-dependent release systems offer targeted drug delivery, allowing prokinetic agents to be released specifically in desired regions of the gastrointestinal tract. This optimizes drug efficacy and minimizes systemic side effects. Gastroretentive formulations enable sustained drug release, which is particularly beneficial in conditions requiring prolonged gastric residence time, such as gastroparesis. Nanoparticles have emerged as promising carriers for improving prokinetic agent delivery and enhancing drug stability, solubility, and absorption. These nano-systems protect drugs from degradation, leading to improved bioavailability and controlled drug release. Furthermore, incorporating mucoadhesive technologies promotes prolonged drug-mucosa interactions, facilitating enhanced drug absorption and reducing dosing frequency. These recent advancements have the potential to revolutionize the oral drug delivery of prokinetic agents, offering improved therapeutic outcomes, enhanced patient compliance, and reduced side effects. However, scalability, biocompatibility, and safety challenges warrant further investigation and validation through preclinical and clinical studies. This review highlights recent advances in oral drug delivery systems for prokinetic agents, focusing on innovative approaches such as pH-dependent release, gastroretentive formulations, nanoparticles, and mucoadhesive technologies. In conclusion, integrating advanced oral drug delivery systems for prokinetic agents presents a promising avenue for managing gastrointestinal disorders. Continued research and collaboration among academia, industry, and healthcare professionals are crucial to unlocking the full potential of these innovations and ultimately translating them into clinically effective treatments for patients.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"125-143"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Recent Developments in Oral Drug Delivery of Prokinetic Agents: Nanoparticles and Beyond.","authors":"Rameshwar Dass, Meenakshi Bhatia, Goutam Rath, Ashwani K Dhingra","doi":"10.2174/1567201823999260310124808","DOIUrl":"10.2174/1567201823999260310124808","url":null,"abstract":"<p><p>In the published version of this article, a discrepancy was identified in the reference numbers provided in Table 7. Citations within Table 7 were numbered up to [228], whereas the article's reference section contained only 224 entries. This inconsistency occurred due to an error in reference numbering during the final preparation of the manuscript. The numbering in Table 7 has now been corrected to align accurately with the reference list. This correction does not affect the article's scientific content, data interpretation, or conclusion. The original article can be found online at: https://www.benthamscience.com/article/145714 The publisher apologizes for this oversight and any inconvenience caused to the authors and readers.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"388"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}